Sun Pharma Q1 FY27 profit rises 27% as sales grow 10%

Key takeaway for investors

Sun Pharmaceutical Industries reported a stronger first quarter in FY27, with consolidated profit rising 27% year-on-year and revenue growing in double digits. The update also came alongside a sharp swing to profit in Sun Pharma Advanced Research Company (SPARC) for the quarter ended March 31, 2026, after three consecutive quarters of losses. Taken together, the numbers highlight two different earnings narratives within the broader Sun Pharma group ecosystem: steady growth led by India and specialty products for Sun Pharma, and a one-quarter financial turnaround for SPARC.

Sun Pharma Q1 FY27: headline numbers

For the quarter ended June 30, 2026 (Q1 FY27), Sun Pharmaceutical Industries’ consolidated net profit attributable to owners rose 27% year-on-year to ₹2,894.79 crore, from ₹2,278.63 crore. Revenue from operations increased 10.5% to ₹15,299.88 crore, from ₹13,851.40 crore.

Another disclosure in the same result set indicated Q1 FY27 sales of ₹15,183.6 crore (₹151.836 billion), up 10.1% from a year earlier. While the two sales figures are presented in different formats, both point to roughly 10% top-line growth for the quarter.

Growth drivers: India formulations and innovative medicines

The company attributed the quarterly performance to strong execution in its India formulations business and continued momentum in its global innovative medicines portfolio. A Reuters report also noted that Sun Pharma’s profit rise was driven by robust growth in its high-margin specialty medicines business, as the company continues to pivot beyond traditional generic drugs.

Sun Pharma also reported that innovative medicines sales rose 12.8% to $151 million during Q1 FY27. The innovative medicines line item was highlighted as a key offset to weaker performance in some parts of the generics portfolio.

Weakness in US formulations

The quarter was not uniformly strong across geographies. The company reported a 9.7% decline in the U.S. business, even as branded generics and innovative medicines helped cushion the impact.

This split matters because U.S. formulations can materially influence growth rates and margins for large Indian pharma exporters. In the Q1 update, the message was that growth in India and specialty products compensated for softness in U.S. formulations.

Margin and operating profitability snapshot

Sun Pharma said gross margin widened to 80.5% in Q1 FY27, and attributed the improvement mainly to a better product mix. EBITDA for the quarter was reported at ₹4,417.7 crore (₹44,177 million), up 2.7% over Q1 last year.

EBITDA margin for the quarter was 28.9%. The company also reported a forex gain of ₹122.0 crore (₹1,220 million), which was lower than Q1 last year.

Profit, EPS, and exceptional items

Reported net profit after tax for Q1 FY27 was ₹2,894.8 crore (₹28,948 million). The company also disclosed an adjusted net profit of ₹3,089.4 crore (₹30,894 million) for the quarter.

EPS for the quarter was ₹12.10 per share. Exceptional items for Q1 FY27 included a charge of ₹167.0 crore (₹1,670 million) toward Organon’s acquisition-related cost, as disclosed by the company.

Reuters context: pivot toward specialty medicines

Reuters summarised the quarter as a continuation of Sun Pharma’s shift toward specialty medicines and away from dependence on traditional generics. The report cited consolidated net profit rising to ₹2,895 crore (₹28.95 billion) for the quarter ended June 30, from ₹2,279 crore (₹22.79 billion) a year earlier, with revenue increasing to about ₹15,300 crore (₹153 billion).

The Reuters framing aligns with the company’s own emphasis on higher-margin specialty and innovative medicines in its quarterly commentary.

SPARC Q4 FY26: profit after three quarters of losses

Separate from Sun Pharma’s Q1 FY27 results, Sun Pharma Advanced Research Company (SPARC) reported a sharp change in its quarterly financials for the quarter ended March 31, 2026 (Q4 FY25-26).

SPARC posted a net profit of ₹1,761.34 crore for Q4 FY26 after three consecutive quarters of losses (as stated in the provided data). The quarterly results table also showed total revenue of ₹1,853.22 crore for the March 2026 quarter, alongside operating income of ₹1,770.80 crore.

The same set of disclosures compared the swing to profitability against prior losses: Q4 FY25 net loss of ₹59.77 crore and Q3 FY26 net loss of ₹80.42 crore.

SPARC ROE spike in FY26 and what it signals

SPARC also reported a return on equity (ROE) of 116.38% for the year ending March 31, 2026, compared with its 5-year average ROE of 22.05% (Standalone Financials, as cited). Such a sharp ROE figure typically reflects unusual year-level profitability or equity base effects. The data point, as provided, indicates FY26 ROE materially above the company’s recent history.

Key numbers at a glance

Market impact and what to track next

For Sun Pharma, the Q1 FY27 result reinforces that growth in India and specialty and innovative medicines can support earnings even when the U.S. business is weaker. Investors will likely track whether the U.S. formulations decline persists, and how the company sustains gross margin at 80.5% and EBITDA margin near 28.9% in subsequent quarters.

For SPARC, the Q4 FY26 return to profit and the FY26 ROE figure stand out, especially given the losses reported in earlier quarters. The key for market participants is to monitor whether the profitability seen in the March 2026 quarter repeats, and how revenue and operating income evolve after the sharp quarter-on-quarter changes shown in the results table.

Conclusion

Sun Pharma’s Q1 FY27 update showed a 27% rise in consolidated profit and around 10% revenue growth, supported by India and innovative medicines, while SPARC posted a Q4 FY26 profit after three loss-making quarters and reported FY26 ROE far above its five-year average. Future quarterly updates will be closely watched for confirmation on the durability of specialty-led margins at Sun Pharma and the sustainability of SPARC’s turnaround.